Salmeterol and fluticasone propionate combined tiotropium in chronic obstructive pulmonary disease,the efficacy analysis

Objective To observe the combined salmeterol and fluticasone propionate with tiotropium in chronic obstructive pulmonary disease(COPD).Methods All of 60 selected patients with COPD were randomly divided into two groups and the control group of 30 cases.Both groups were symptomatic with normal oxygen and other nutrients to support treatment,while the control group using salmeterol and fluticasone propionate(Seretide,50/500 μg,the British company GlaxoSmithKline) treatment;observation group were based the combination of tiotropium(Spiriva,18 μg / tablets,Boehringer Ingelheim Pharmaceutical Co.Ltd.).Results After 6 months,the clinical symptoms observed group score(7.2±2.3) points,the control group was(4.0±1.6) points,the difference was significant(P 0.05).The total effective observation group(93.33%) was significantly higher(73.33%),significant difference(P 0.05).All patients were no significant adverse reactions.Conclusion Salmeterol and fluticasone propionate combined tiotropium in chronic obstructive pulmonary disease(COPD) the effective,can significantly improve the clinical symptoms,safety,and worthy of extensive promotion and application.